For instance, an ongoing trial is using non-modified SKNLP and modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cell lines for vaccination of high-risk neuroblastoma patients (NCT00101309). The gene discussed is IL2; the disease is neuroblastoma.